SEEL Seelos Therapeutics Inc.

2.64
-0.1  -4%
Previous Close 2.74
Open 2.68
Price To Book 20.31
Market Cap 56171885
Shares 21,277,229
Volume 278,238
Short Ratio
Av. Daily Volume 3,314,111

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dosing to be initiated 3Q 2019.
Trehalose
Sanfilippo syndrome/MPS III
Phase 1 trial to be initiated 3Q 2019.
SLS-002
Post-traumatic stress disorder (PTSD)